Consider what happens in the first forty minutes of a major trauma case. A patient is extracted from a vehicle. Vital signs are taken at the scene, then again in the ambulance. A paramedic calls ahead. The patient arrives. A trauma team assembles, reads a paper handover form, and begins its own assessment from scratch. In those forty minutes, an extraordinary amount of data was generated: temperature trajectory, transfer duration, pressure distribution, oxygen saturation tren

I come from investment, not medicine. Twenty years in healthcare finance teaches you to look for the gap between what a problem costs and what it would cost to solve it. When Jeremy Mauger described what he was watching happen to patients on cold, hard scoop stretchers with multiple transfers between trolleys — core temperatures dropping during transfer, clotting systems already failing by the time they reached the resuscitation room — the gap was obvious. The clinical evide

In trauma, both physical injury and physiological deterioration can impact mortality. A patient is extracted from a road traffic collision. The injury is potentially survivable. We stop the haemorrhage, secure the airway, ensure respiration and circulation are stable and then consider hypothermia. This is all in line with the MARCH protocols for trauma. By the time that patient reaches the resuscitation room, their core temperature is dangerously below 35 ℃, that is below the

How Impact Investing is bringing investors and charities into the same Innovation space Healthcare innovation is increasingly being driven both by investors and charities. Some investors are now demanding demonstrable social impact. Some charities, long accustomed to grant‑based funding cycles, are seeking new ways to ensure donor capital delivers sustainable, scalable change. Impact investing sits at the centre of this convergence. Nowhere is this more visible than in Medtec